Immunotherapy Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Immunotherapy Drugs Market: By Drugs (Vaccines (Preventive Vaccines, Therapeutic Vaccines), Monoclonal Antibodies, Interferons Alpha & Beta, Checkpoint Inhibitors, Interleukins, and Others), By Therapy Area (Autoimmune & Inflammatory Diseases, Cancer, Infectious Diseases, and Others), By End User (Hospitals/Clinics, Cancer Research Centre, and Others), and Geography

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global immunotherapy drugs market size was valued at USD 159.13 Billion in 2021 and is projected to reach USD 355.34 Billion by 2028, growing at a CAGR of 10.4% from 2022 to 2028 due to surge in the prevalence of chronic diseases. According to International Agency for Research on Cancer (IACR) in 2018, 18.1 Mn people are estimated to be suffering from cancer worldwide, which is expected to reach 29.5 Mn by 2040. Moreover, rising demand and development of monoclonal antibodies (mAbs) and emergence of biosimilars are the major factors that are driving the growth of the immunotherapy drugs market. Additionally, favorable reimbursement policies and support by the government fuels the growth of the market. However, High cost of treatment for chronic diseases hinders the growth of the market over forecast period. Global immunotherapy drugs market is surging owing to strategic collaborations and definitive agreements between the market players to develop and commercialize product in the market. For instance, In March 2018, Inovio collaborated with ApolloBio Corp, and provided exclusive right to develop, manufacture and commercialize VGX-3100, a DNA immunotherapy, in greater China. In March 2018, Novartis collaborated with Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute for developing next generation biomaterials systems to deliver immune-oncology therapies.

Immunotherapy Drugs Market

MARKET SUMMARY
-
10.4%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 10.4%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Immunotherapy Drugs Market

  • Global immunotherapy drugs market report gives comprehensive outlook on immunotherapy drugs across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global immunotherapy drugs market gives historical, current, and future market sizes (US$ Bn) on the basis of drugs type, therapy area, end user, and region.
  • This report studies global immunotherapy drugs market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
  • Key stakeholders of the global immunotherapy drugs market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global immunotherapy drugs products.
Market Key Players
  • AbbVie Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • AstraZeneca plc. (U.K.)
  • Bristol-Myers Squibb (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Johnson & Johnson (U.S.)
Growth

Immunotherapy Drugs Market

Rising adoption of targeted therapies and quick drug approval processes and rising prevalence rate of lifestyle diseases drives the growth of the market for Immunotherapy drugs. Cancer segment is the fastest growing segment by therapy area owing to increasing prevalence of cancer and the preference of immunotherapy as the first line of treatment for cancer. Rising demand for monoclonal antibodies and development of monoclonal antibodies coupled with the emergence of new biosimilars into the market enhances the growth of the market.


North-America Got Significant Share

Immunotherapy Drugs Market

North America accounted for larger revenue share in global immunotherapy drugs market with significant CAGR owing to presence of large number of market players and development and launch of new molecules into the market. Asia Pacific region is expected to be the fastest growing region over the forecast period due to acceptable regulatory scenario in the region and low cost of drug manufacturing attributes to the growth of the market. Europe market is expected to show the significant growth rate over the forecast years.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Findings of the Report

  • Global immunotherapy drugs market expanding at significant CAGR over 2022 to 2028 owing to rising demand for monoclonal antibodies and emergence of biosimilars coupled with increase in prevalence of chronic diseases.
  • Based on therapy area, cancer segment immunotherapy drugs accounted for larger market revenue share in 2021 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global immunotherapy drugs market

Key

Key Features of the Report

Immunotherapy Drugs Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary
2. Global Immunotherapy Drugs Market Introduction
2.1. Global Immunotherapy Drugs Market – Taxonomy
2.2. Global Immunotherapy Drugs Market –Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By End User
2.2.4. By Region
3. Global Immunotherapy Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Immunotherapy Drugs Market Dynamic Factors – Impact Analysis
3.6. Global Immunotherapy Drugs Market – Competition Landscape
4. Global Immunotherapy Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Immunotherapy Drugs Market, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Checkpoint Inhibitors (CI)
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Monoclonal Antibodies (mAbs)
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Interferons & Interleukins (IFs & ILs)
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Immunotherapy Drugs Market, By Application, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Autoimmune & Inflammatory Diseases
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Infectious Diseases
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Immunotherapy Drugs Market, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. Hospitals
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Clinics
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Immunotherapy Drugs Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Immunotherapy Drugs Market – Opportunity Analysis Index, By Type, Application, End User, and Region, 2022 – 2028
9. North America Immunotherapy Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Checkpoint Inhibitors (CI)
9.1.2. Monoclonal Antibodies (mAbs)
9.1.3. Interferons & Interleukins (IFs & ILs)
9.1.4. Others
9.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Cancer
9.2.2. Autoimmune & Inflammatory Diseases
9.2.3. Infectious Diseasess
9.2.4. Others
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Immunotherapy Drugs Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022 – 2028
9.6. North America Immunotherapy Drugs Market Dynamics – Trends
10. Europe Immunotherapy Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Checkpoint Inhibitors (CI)
10.1.2. Monoclonal Antibodies (mAbs)
10.1.3. Interferons & Interleukins (IFs & ILs)
10.1.4. Others
10.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Cancer
10.2.2. Autoimmune & Inflammatory Diseases
10.2.3. Infectious Diseasess
10.2.4. Others
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Others
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Immunotherapy Drugs Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022 – 2028
10.6. Europe Immunotherapy Drugs Market Dynamics – Trends
11. Asia-Pacific Immunotherapy Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Checkpoint Inhibitors (CI)
11.1.2. Monoclonal Antibodies (mAbs)
11.1.3. Interferons & Interleukins (IFs & ILs)
11.1.4. Others
11.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Cancer
11.2.2. Autoimmune & Inflammatory Diseases
11.2.3. Infectious Diseasess
11.2.4. Others
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Others
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Immunotherapy Drugs Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022 – 2028
11.6. Asia-Pacific Immunotherapy Drugs Market Dynamics – Trends
12. Latin America Immunotherapy Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Checkpoint Inhibitors (CI)
12.1.2. Monoclonal Antibodies (mAbs)
12.1.3. Interferons & Interleukins (IFs & ILs)
12.1.4. Others
12.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Cancer
12.2.2. Autoimmune & Inflammatory Diseases
12.2.3. Infectious Diseasess
12.2.4. Others
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Others
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Immunotherapy Drugs Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022 – 2028
12.6. Latin America Immunotherapy Drugs Market Dynamics – Trends
13. Middle East and Africa Immunotherapy Drugs Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Checkpoint Inhibitors (CI)
13.1.2. Monoclonal Antibodies (mAbs)
13.1.3. Interferons & Interleukins (IFs & ILs)
13.1.4. Others
13.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Cancer
13.2.2. Autoimmune & Inflammatory Diseases
13.2.3. Infectious Diseasess
13.2.4. Others
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Others
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. MEA Immunotherapy Drugs Market – Opportunity Analysis Index, By Type, Application, End User, and Country, 2022 – 2028
13.6. MEA Immunotherapy Drugs Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Pfizer Inc
14.2.2. AstraZeneca
14.2.3. Johnson & Johnson
14.2.4. Novartis International AG
14.2.5. GlaxoSmithKline Plc
14.2.6. Merck & Co
14.2.7. AbbVie Inc
14.2.8. Immatics Biotechnologies
14.2.9.  Amgen Inc.
14.2.10. F. Hoffmann-La Roche Ltd
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • Pfizer Inc
  • AstraZeneca
  • Johnson & Johnson
  • Novartis International AG
  • GlaxoSmithKline Plc
  • Merck & Co
  • AbbVie Inc
  • Immatics Biotechnologies
  • Amgen Inc.
  • Hoffmann-La Roche Ltd

Description

The global immunotherapy drugs market size was valued at USD 159.13 Billion in 2021 and is projected to reach USD 355.34 Billion by 2028, growing at a CAGR of 10.4% from 2022 to 2028 due to surge in the prevalence of chronic diseases. According to International Agency for Research on Cancer (IACR) in 2018, 18.1 Mn people are estimated to be suffering from cancer worldwide, which is expected to reach 29.5 Mn by 2040. Moreover, rising demand and development of monoclonal antibodies (mAbs) and emergence of biosimilars are the major factors that are driving the growth of the immunotherapy drugs market. Additionally, favorable reimbursement policies and support by the government fuels the growth of the market. However, High cost of treatment for chronic diseases hinders the growth of the market over forecast period. Global immunotherapy drugs market is surging owing to strategic collaborations and definitive agreements between the market players to develop and commercialize product in the market. For instance, In March 2018, Inovio collaborated with ApolloBio Corp, and provided exclusive right to develop, manufacture and commercialize VGX-3100, a DNA immunotherapy, in greater China. In March 2018, Novartis collaborated with Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute for developing next generation biomaterials systems to deliver immune-oncology therapies.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX